Myasthenia gravis is stratified by antibody subtype, not severity; only the roughly 85% of US patients who are AChR-positive can access C5 inhibitors.

Myasthenia gravis is an autoantibody-mediated disorder of the neuromuscular junction. Antibodies against the acetylcholine receptor, muscle-specific kinase, or LRP4 disrupt signal transmission and produce fluctuating, fatigable weakness. US prevalence is estimated at 100,000 to 200,000 patients, with recognised underdiagnosis. The population divides by serology: roughly 85% are AChR-antibody positive, about 5% MuSK-antibody positive, around 2% LRP4-positive, and 8 to 10% seronegative. Because AChR-mediated disease is complement-driven at the nerve-muscle junction, the C5 inhibitor class is approved only in the AChR-positive subgroup, making serology the commercial gate as much as the clinical one.

Severity is defined by the myasthenic crisis: respiratory failure requiring intubation and ICU support. An estimated 15% to 20% of patients experience at least one crisis in their lifetime, most often triggered by infection, with roughly 4% mortality per episode. Historical series show a median of about 13 days to extubation, with older age and low post-intubation vital capacity predicting a longer ventilator stay. The outstanding evidence gap is comparative effectiveness: which patients benefit most from FcRn blockade, complement inhibition, or traditional immunosuppression remains unresolved.

Antibody serology, not symptom severity, decides who can access which drug class.

Five questions this report answers:

Q1 - What is the AChR / MuSK / LRP4 / seronegative split of US gMG patients?

Q2 - How common and how dangerous is a myasthenic crisis in gMG patients?

Q3 - Where does misdiagnosis concentrate along the US gMG diagnostic pathway?

Q4 - What share of US myasthenia gravis patients are AChR-antibody positive?

Q5 - What triggers a myasthenic crisis, and how often is it fatal?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #gMG #Neurology #RareDisease #USHealthcare #Autoimmune

Live report page:  https://axlrx.ai/myasthenia-gravis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Efgartigimod's June 2025 NICE rejection (TA1069) leaves roughly 4,000 UK generalised MG patients without a recommended novel agent.

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction, most commonly driven by AChR antibodies in 85% of generalised MG, with anti-MuSK and anti-LRP4 subtypes accounting for the remainder. An estimated 7,000-10,000 UK patients have generalised MG; diagnosis is confirmed via AChR-Ab testing at routine NHS immunology labs available at every NHS trust, with anti-MuSK and anti-LRP4 testing reserved for specialist neuromuscular labs. The NHS neuromuscular network comprises approximately 30 specialist centres coordinated through the Muscular Dystrophy UK network, and the Myasthenia Gravis Association UK maintains a patient registry of roughly 3,000 enrolled members.

Eculizumab's own MG appraisal (TA636) was terminated in 2020 after the manufacturer chose not to submit a cost-effectiveness dossier, so NICE never modelled a cost-per-QALY figure for eculizumab in MG. Efgartigimod's appraisal concluded with final guidance TA1069, published 4 June 2025: NICE does not recommend efgartigimod for NHS use, citing gaps and uncertainties in the cost-effectiveness evidence. As a result, an estimated 4,000 UK moderate-to-severe gMG patients remain on the pyridostigmine plus corticosteroid, azathioprine, or mycophenolate backbone, with IVIg or plasma exchange reserved for crises. MGA UK survey data estimate that 30-40% of UK gMG patients have inadequate disease control on current standard therapy.

No novel agent has cleared NICE, leaving inadequate control unresolved for many patients.

Five questions this report answers:

Q1 - What is the size of the UK gMG population with inadequate control after TA1069's rejection?

Q2 - What is the NHS diagnostic pathway for MG, including thymoma screening and thymectomy eligibility?

Q3 - Why was eculizumab's MG appraisal withdrawn, and what does efgartigimod's TA1069 rejection mean next?

Q4 - How many UK patients does the Myasthenia Gravis Association's registry currently enrol?

Q5 - What share of AChR-positive cases account for generalised myasthenia gravis in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #NICE #NHS #UK #RareDisease #DiseaseLandscape

Live report page:  https://axlrx.ai/myasthenia-gravis/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Just 8-10 GCC neurologists manage 70-80% of confirmed myasthenia gravis, yet 30-40% are first misdiagnosed as thyroid myopathy.

Myasthenia gravis affects an estimated 6,000 to 10,000 patients across the GCC, or 14 to 20 per 100,000, diagnosed via acetylcholine receptor antibody testing available at specialist neurology and immunology laboratories including KFSH&RC, AUH, Hamad Medical Corporation, and SKMC. The region's high background prevalence of thyroid disease creates a significant diagnostic confounder: thyroid eye disease and thyroid myopathy produce similar ptosis and fatigable weakness, and an estimated 30% to 40% of GCC MG patients are misdiagnosed as thyroid myopathy at first presentation, a distinctly GCC-shaped diagnostic trap rarely emphasised in Western literature.

That diagnostic delay has clinical consequences: GCC case series show 60% to 70% of patients present at MGFA Class III to IV, moderate-severe oculobulbar and limb weakness, versus approximately 40% in European series, with myasthenic crisis occurring at a higher proportion, tied to delayed diagnosis and late immunosuppressive therapy. Thymoma, present in 10% to 15% of MG patients, is worked up in most tertiary GCC referrals but not routinely elsewhere, and thymectomy capacity for non-thymoma cases remains limited. The concentration is stark: an estimated 8 to 10 neurologists across KSA, UAE, and Qatar tertiary centres manage 70% to 80% of all confirmed GCC generalised MG.

A thyroid look-alike hides myasthenia gravis until disease is already advanced.

Five questions this report answers:

Q1 - How does the thyroid-disease diagnostic confounder shape GCC MG time-to-diagnosis?

Q2 - Which 8-10 GCC neurologists manage most confirmed generalised MG, and what does concentration mean commercially?

Q3 - What is the NPHC/MOH formulary trajectory for efgartigimod against the pyridostigmine-plus-steroid backbone?

Q4 - What diagnostic and access barriers define the addressable GCC myasthenia gravis market?

Q5 - How often does thymoma occur in MG patients, and where is it worked up in the GCC?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #Neurology #FcRn #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/myasthenia-gravis/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

US MASH's commercial pool is not the 86.3 million with fatty liver; it is the 6.7 million with F2-F3 fibrosis, and most are unstaged.

MASH is the progressive, inflammatory form of fatty liver disease in which fat accumulation drives liver injury and fibrosis, renamed from NASH under the 2023 multi-society consensus. It sits inside a wide funnel: 86.3 million US adults have fatty liver disease, 14.9 million have MASH, and 6.7 million have MASH with clinically significant fibrosis, the FDA label-eligible pool, projected to rise to 11.7 million by 2050. Fibrosis stage, not the amount of fat in the liver, is what tracks with liver-related outcomes, so the treatable population is defined by staging rather than by the underlying disease's full size.

Fibrosis is graded from F0 to F4, and the treatable band sits at F2, significant, to F3, advanced but not yet cirrhosis; compensated cirrhosis is excluded from both approved agents and is what the next wave of pipeline drugs is chasing. The real constraint, though, is diagnosis, not disease size: most of the 6.7 million eligible patients are undiagnosed or unstaged in primary care. The standard pathway uses a blood test called FIB-4 to sort patients, then refers anyone in the indeterminate range to an elastography scan. Where that referral does not happen, eligible patients never reach a labeled therapy at all.

Diagnosis, not drug efficacy, is the real bottleneck in the US MASH market.

Five questions this report answers:

Q1 - How large is the US F2-F3 label-eligible MASH pool today?

Q2 - How is at-risk MASH staged without a liver biopsy in practice?

Q3 - Which MASH patients fall outside the label boundary entirely?

Q4 - How many US adults are actually eligible for MASH drug treatment?

Q5 - What FIB-4 and elastography thresholds gate a MASH diagnosis?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MASH #FattyLiverDisease #Hepatology #Rezdiffra #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/mash/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

IgA nephropathy is the most common primary glomerulonephritis, yet it had no disease-specific therapy until 2021, and 30-40% of patients still progress to kidney failure.

IgA nephropathy is a primary glomerular disease driven by circulating galactose-deficient IgA1: autoantibodies form immune complexes that deposit in the glomerular mesangium, activate complement and drive progressive kidney injury. It is the most common biopsy-proven primary glomerulonephritis. In a large, racially and ethnically diverse US population, adult incidence ran roughly 1.29 to 2.2 new cases per 100,000 per year, highest among patients of Asian ancestry and lowest among Black patients. Because a confirmed diagnosis requires a kidney biopsy, milder disease managed simply as chronic kidney disease without biopsy goes uncounted, so the diagnosed pool understates true prevalence.

The disease is slow but rarely benign. Between 30% and 40% of patients progress to end-stage kidney disease over 20 to 30 years, and registry data put median kidney survival at roughly 11 years from diagnosis for patients under nephrology follow-up. Proteinuria and eGFR trajectory are the validated markers of long-term outcome, and that evidence base underwrote a fast-moving therapeutic shift: from renin-angiotensin-system blockade plus an SGLT2 inhibitor as the supportive-care backbone to five FDA-approved disease-modifying agents spanning four mechanisms, approved between 2021 and 2026.

The therapeutic shift outpaced the diagnostic pathway that still gates it.

Five questions this report answers:

Q1 - How large is the US IgAN population, and how much disease does the biopsy requirement miss?

Q2 - How do kidney biopsy and the Oxford MEST-C classification define IgAN risk?

Q3 - How does the 2021-2026 approval wave change management alongside KDIGO 2025 guidance?

Q4 - How does IgAN incidence vary by race and ethnicity in the US?

Q5 - What share of IgAN patients progress to kidney failure over time?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #IgAN #KidneyDisease #Nephrology #RareDisease #USHealthcare

Live report page:  https://axlrx.ai/iga-nephropathy/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

IgA nephropathy drives 10-12% of incident UK end-stage renal disease, a burden NICE built into its budesonide and sparsentan case.

IgA nephropathy is an immune-mediated glomerulonephritis caused by mesangial deposition of galactose-deficient IgA1, driving progressive proteinuria and declining eGFR. The UK Renal Registry identifies IgAN as the UK's second most common primary glomerulonephritis after membranous nephropathy, with an estimated 10,000-15,000 UK patients and approximately 500 new diagnoses a year confirmed via kidney biopsy. IgAN accounts for 10-12% of incident UK end-stage renal disease, roughly 1,000-1,200 UK ESRD cases annually. A network of approximately 80 NHS specialist nephrology centres performs the confirmatory biopsies, giving the UK a comparatively high diagnosis rate.

The Renal Association's IgAN guideline, aligned with KDIGO 2021, directs optimal ACEi/ARB therapy for three to six months before considering novel agents, targeting blood pressure below 130/80mmHg and a UPCR below 0.5g/g. Corticosteroid immunosuppression remains controversial following the STOP-IgAN trial's null result in high-risk patients, with SGLT2 inhibition now being explored. Both novel agents have since cleared NICE technology appraisal: targeted-release budesonide under TA937, updated by TA1128 in 2026, and sparsentan under TA1074 in June 2025, following MHRA approval of sparsentan in April 2025, moving IgAN novel-agent access from a Named Patient Programme into mainstream NHS commissioning.

Two novel agents cleared NICE; the eligible population sits behind ACEi/ARB failure first.

Five questions this report answers:

Q1 - What is the size of the UK IgAN population eligible for novel agents after ACEi/ARB fails?

Q2 - What is the NHS economic case for novel IgAN agents built on ESRD cost offset?

Q3 - How do the budesonide (TA937/TA1128) and sparsentan (TA1074) NICE recommendations compare on funding?

Q4 - How many NHS nephrology centres perform the biopsies that confirm an IgAN diagnosis?

Q5 - Why did the STOP-IgAN trial leave corticosteroid use controversial in high-risk patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #UKRenal #NICE #NHS #NephrologyMarket #DiseaseLandscape

Live report page:  https://axlrx.ai/iga-nephropathy/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

GCC nephrologists biopsy fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany, masking IgAN.

IgA nephropathy is estimated to affect 8,000 to 12,000 patients across the GCC, but the true IgAN fraction of incident CKD is difficult to establish. Most proteinuric patients in the region are attributed to diabetic nephropathy, reflecting the GCC's 35% to 40% adult diabetes prevalence, without a confirmatory kidney biopsy. KDIGO guidance calls for biopsy in non-diabetic proteinuria, yet a GCC nephrology network capacity survey finds biopsy performed in fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany. Under-biopsy is functionally equivalent to under-diagnosis: a patient never biopsied cannot be coded as IgAN.

Once diagnosed, GCC IgAN patients progress to end-stage renal disease 15% to 20% faster than European observational cohorts, consistent with later diagnosis, poorly controlled hypertension (mean systolic blood pressure at diagnosis of 148mmHg versus a sub-130mmHg target), and late initiation of ACE inhibitor or ARB therapy. Kidney biopsy capability is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams; the patient journey from proteinuria detection to diagnosis typically takes 12 to 24 months, roughly double the 6 to 12 month European benchmark. GCC patients reaching ESRD represent a meaningful share of the region's dialysis population, with IgAN contributing an estimated 12% to 15%.

Diabetes is absorbing a kidney disease population that biopsy would reveal.

Five questions this report answers:

Q1 - How large is the true GCC IgAN population once corrected for diabetes misattribution?

Q2 - Which GCC nephrology centres have kidney biopsy capacity, and how does that gate access to novel therapy?

Q3 - What does ACEi/ARB-first standard of care mean for budesonide and sparsentan entry?

Q4 - What diagnostic and access barriers define the addressable GCC IgA nephropathy market?

Q5 - Why do GCC IgAN patients reach ESRD 15-20% faster than European cohorts?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #Nephrology #RareDisease #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/iga-nephropathy/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

One in 50,000 Americans has HAE, yet laryngeal attacks are just 0.9% of episodes and still drive nearly all its mortality.

Hereditary angioedema is an autosomal-dominant disorder of the SERPING1 gene that leaves C1-esterase inhibitor either too scarce (Type I, roughly 85% of patients) or too dysfunctional (Type II, roughly 15%). The result is unchecked plasma-kallikrein activity and bradykinin overproduction, the mediator behind recurrent, non-itchy swelling that has nothing to do with a typical allergic reaction. US prevalence sits near 1 in 50,000, based on patient-advocacy estimates rather than a peer-reviewed count, and because inheritance is autosomal dominant, every child of an affected parent carries a 50% risk of inheriting the condition.

Symptoms typically begin around age 11 and recur for life. A natural-history cohort of 221 patients tracked 131,110 attack episodes and found cutaneous and abdominal swellings made up 97.4% of them, while laryngeal episodes were only 0.9%, yet they carry essentially all of the disease's mortality risk. Abdominal attacks bring crampy pain, vomiting in 73% of episodes and diarrhoea in 41%, closely mimicking an acute abdomen and often leading to unnecessary surgery before HAE is even considered. Laryngeal attacks kill disproportionately in patients whose disease was never diagnosed, which is why diagnosis, confirmed by a low C4 alongside reduced C1-inhibitor level or function, matters more than any new therapy.

Earlier recognition, not new therapy, is the pivotal commercial and clinical lever.

Five questions this report answers:

Q1 - How large is the US HAE population, and how does the Type I/II split shape the prophylaxis pool?

Q2 - What does the HAE attack burden look like across cutaneous, abdominal and laryngeal attacks?

Q3 - Where is the diagnostic delay in US HAE, and what is the undiagnosed pool worth commercially?

Q4 - How do Type I and Type II HAE differ in C1-inhibitor levels and function?

Q5 - Which HAE attacks are most dangerous, and why do they carry the highest mortality risk?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HereditaryAngioedema #HAE #RareDisease #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/hereditary-angioedema/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/